August 9, 2017 09:05 AM EDTUpdated 09:43 AM
People
Financing
Startups

Soft­Bank bets $1.1B on Roivant CEO Vivek Ra­maswamy’s brash new biotech strat­e­gy

John Carroll

Editor & Founder

With piv­otal da­ta loom­ing on his first big biotech play, Vivek Ra­maswamy just land­ed a whop­ping $1.1 bil­lion in­vest­ment to back the ex­plo­sive growth of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

A service from the Financial Times